Has Michael Rausch, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,109,877 in general payments to Michael Rausch, MD across 2,574 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Rausch, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Rausch, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Rausch, MD

Family Medicine · Augusta, KSNPI 1528173705

Payments from drug & device makers

$8,109,877in general payments, 2019–2025

Across 2,574 payments — averaging $3150.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Modernatx, Inc.$3.1M
Pfizer$932K
GSK$772K
Emergent Biosolutions Inc.$731K
Valneva Austria GmbH$598K
Seqirus USA Inc$286K
plus $1.7M from 39 others

$75,412in research payments, 2019–2025

Across 9 payments — averaging $8379.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Valneva Austria GmbH$72K
Eli Lilly$2K
Lexicon Pharmaceuticals, Inc.$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Modernatx, Inc.	518	$3,089,701
Pfizer	256	$932,147
GSK	173	$772,295
Emergent Biosolutions Inc.	849	$730,927
Valneva Austria GmbH	29	$598,375
Seqirus USA Inc	228	$286,175
Johnson & Johnson	49	$275,660
Sanofi Pasteur Inc.	38	$265,302
Janssen Research & Development, LLC	18	$263,396
Merck	160	$195,425
Eli Lilly	14	$148,967
Vertex	2	$128,693
Currax Pharmaceuticals LLC	24	$99,851
AstraZeneca	37	$96,557
AbbVie	67	$94,243
Alnylam Pharmaceuticals Inc.	18	$27,492
Boehringer Ingelheim	3	$25,838
Takeda Pharmaceuticals U.S.A., Inc.	5	$24,835
Lexicon Pharmaceuticals, Inc.	5	$21,003
Astrazeneca UK Limited	2	$19,255
Boehringer Ingelheim Pharma GmbH & Co.kg	3	$10,015
Biohaven Pharmaceutical Holding Company Ltd.	3	$1,385
Boehringer Ingelheim International GmbH	12	$909
Bayer	14	$331
Lilly USA, LLC	17	$247
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$139
Novo Nordisk	1	$125
Amgen	2	$117
Teva Pharmaceuticals USA, Inc.	1	$73
Cranial Technologies, Inc	3	$55
Novartis	3	$46
Ironshore Pharmaceuticals Inc.	2	$38
Exact Sciences	2	$29
Kowa Pharmaceuticals America, Inc.	2	$28
Sumitomo Pharma America, Inc.	1	$24
Axsome Therapeutics, Inc.	1	$23
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$22
Eisai Inc.	1	$21
Zyla Life Sciences, Inc.	1	$20
Corium, LLC	1	$20
Mylan Specialty L.p.	1	$16
CTL Medical Corporation	2	$15
Avanir Pharmaceuticals, Inc.	1	$14
Edwards Lifesciences	1	$13
Daiichi Sankyo Inc.	1	$11

How this compares

$8,109,877 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas →

Medicare billing

Part B allowed, 2024

$25,601

Medicare patients

Services billed

406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Augusta

Terry PolingWichita$24.2M
Richard GloverNewton$19.6M
Daniel DickersonLenexa$13.6M
Patrick YaoOlathe$11.7M
Terry KleinWichita$5.9M
Richard EgelhofWichita$4.1M
Thomas KleinWichita$3.4M
Troy HoldemanNewton$3.2M
Stacy SlechtaNewton$3M
Brandon AllemanWichita$3M

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →